Main Uses and Therapeutic Benefits

Colchicine Stada is a medicinal product primarily utilized for the management and prevention of gout flares. It contains the active substance colchicine, which is derived from the autumn crocus plant and has been used for centuries to address inflammatory conditions related to uric acid crystal deposition.

Treatment of Acute Gout Attacks

The primary application of Colchicine Stada is the treatment of acute gouty arthritis. Gout is a form of inflammatory arthritis characterized by the sudden onset of severe pain, swelling, and redness, typically in a single joint such as the big toe. These symptoms are caused by the body's inflammatory response to monosodium urate crystals that have accumulated in the joint space.

Colchicine works by interfering with the inflammatory cycle. It reduces the migration of white blood cells (leukocytes) to the affected area and inhibits the phagocytosis of uric acid crystals, which helps to alleviate the intense pain and inflammation associated with a flare-up.

Prevention of Gout Flares

In addition to treating active symptoms, Colchicine Stada is used as a prophylactic measure. Patients starting on urate-lowering therapies, such as allopurinol, often experience a temporary increase in gout attacks as uric acid levels in the blood shift and crystals begin to dissolve.

Colchicine is frequently prescribed during the initial months of these long-term treatments to stabilize the joints and prevent the occurrence of breakthrough flares. This helps patients maintain a better quality of life while their underlying uric acid levels are being managed.

Other Applications

While gout is the most common indication, colchicine is also utilized in the treatment of Familial Mediterranean Fever (FMF). FMF is a hereditary autoinflammatory disorder that causes recurrent episodes of fever and painful inflammation in the abdomen, chest, or joints. In this context, the medication helps to reduce the frequency and severity of these episodes and serves to prevent long-term complications associated with chronic inflammation, such as amyloidosis.

Regulatory References

1. NIH MedlinePlus Drug Information

Colchicine Stada's eligibility is strictly defined by regulatory authorities based on patient health status and age. The medicine is absolutely contraindicated for specific populations where the risk of toxicity is critically high.

Contraindicated Populations (Must Not Use)

Classification	Population/Condition
Absolute Prohibition	Patients with severe renal impairment (kidney disease), severe hepatic impairment (liver disease), or pre-existing blood dyscrasias (e.g., bone marrow suppression).
Drug-Linked Prohibition	Patients with renal or hepatic impairment who are concurrently taking strong inhibitors of the CYP3A4 or P-gp enzymes, due to risk of fatal toxicity.

Populations with Restricted or Conditional Use

• Mild-to-Moderate Impairment: Use requires caution and close monitoring in patients with mild or moderate renal or hepatic impairment, as well as in elderly or debilitated patients.
• Age Limits: The medicine is approved for adults for gout and for children 4 years of age and older for Familial Mediterranean Fever (FMF). Use is not recommended for children and adolescents in the treatment or prophylaxis of gout flares.
• Reproductive Status: The EMA classifies use during pregnancy and breastfeeding as contraindicated. The FDA advises use only if the potential benefit justifies the risk. Male patients should be aware of a transient risk of fertility impairment.

Interactions with other medicines and products

The official interaction profile of colchicine, the active ingredient in Colchicine Stada, is highly influenced by its clearance pathways. Colchicine is a substrate for the CYP3A4 metabolic enzyme and the P-glycoprotein (P-gp) efflux transporter. The co-administration of medicines that inhibit these pathways significantly increases colchicine's systemic exposure, raising the risk of toxicity.

Contraindicated Combinations and Exposure Modification

Co-administration with strong CYP3A4 inhibitors (e.g., Clarithromycin, Itraconazole) or P-gp inhibitors (e.g., Ciclosporin, Verapamil) can cause a clinically significant increase in plasma concentration ( C max and AUC). This combined use is officially contraindicated in patients with pre-existing renal impairment or hepatic impairment due to the heightened risk of serious adverse effects.

Pharmacodynamic and Substance Interactions

Regulatory documentation notes an increased risk of myopathy and rhabdomyolysis when colchicine is combined with other myotoxic agents, such as statins or fibrates. Furthermore, co-consumption of grapefruit juice is documented to potentially increase colchicine levels by inhibiting its clearance and should be avoided. Colchicine may also induce a reversible malabsorption of Vitamin B12.

Disruption of Cellular Mobility (Microtubule Inhibition)

This domain centers on the drug's primary action: the specific binding to the tubulin protein, which prevents the assembly of microtubules. This structural blockade impairs the ability of key immune cells, primarily neutrophils, to migrate and physically infiltrate tissue. This physiological change results in a limitation of cellular infiltration that would otherwise propagate the acute inflammatory response.

---

️ Suppression of Pro-inflammatory Signaling (NLRP3 Modulation)

This domain covers the drug's action on immune chemistry by interfering with the activation of the NLRP3 inflammasome complex. This interference significantly reduces the body's output of inflammatory chemical messengers, such as Interleukin-1beta (IL-1beta). Modulating this critical signaling pathway results in the suppression of the systemic chemical cascade that recruits and activates immune cells.

---

️ Functional Selectivity and Dual Cascade Effect

Colchicine's overall effect is achieved through the coordinated impact of these two mechanisms—blocking both the physical cellular response and the chemical signaling trigger—at concentrations that selectively accumulate within leukocytes. This functional selectivity facilitates the modulation of highly dynamic inflammatory pathways, resulting in a constraint on processes that propagate acute inflammatory responses.

How to Use Colchicine Stada

Colchicine Stada is administered exclusively via the oral route, and the tablets must be swallowed whole, generally with water. The medicine may be taken without regard to meals. The usage protocol is determined by the clinical application, differentiating between a brief, high-intensity course and a continuous, long-term regimen.

Dosing Regimens

Application	Standard Adult Dosing	Administration Principle
Acute Gout Flare	An initial dose of 1.2 mg followed by 0.6 mg one hour later (total 1.8 mg).	Short-term course, administered over 1 hour.
Gout Prophylaxis	0.6 mg once or twice daily (maximum 1.2 mg/day).	Long-term, continuous administration.
FMF & ASCVD	Ranges from 0.5 mg to 2.4 mg daily, often in divided doses (for FMF).	Long-term, maintenance regimen.

A critical procedural condition dictates that a treatment course for an acute gout flare must not be repeated for at least three days (72 hours) following its completion. For long-term use, the dose may be administered once daily or in divided doses; if a regular dose is missed, it is recommended to skip the missed dose and take the next dose at the scheduled time.

Dose adjustments are required for specific populations. A reduction in dosage is necessary for individuals with severe renal or hepatic impairment to manage systemic exposure.

Research evidence / Overview of Studies for Colchicine Stada

This overview summarizes the research evidence and clinical evaluation of the medicine, based on data reported in authoritative sources such as government health agencies and peer-reviewed scientific literature. This information focuses only on the scope and findings of the research and does not provide clinical guidance or treatment advice.

---

Evidence for Use in Gout (Acute Flares and Prophylaxis)

The research foundation for this use includes short-term and intermediate-term Randomized Controlled Trials (RCTs). These studies were used to explore how the medicine influences short-term symptom patterns during a flare and to assess its use for flare prevention. Researchers monitored outcomes related to physical discomfort by tracking daily pain intensity scores and monitored how symptoms evolved in the observed populations during the study period. Studies conducted during periods of increased symptom activity reported measurements of pain intensity scores. The evidence contributes to the broader evidence landscape for research exploring this medicine in conditions involving periods of heightened symptoms. Regarding the research structure, detailed data on outcomes reflecting daily functioning remain limited.

---

Evidence for Use in Familial Mediterranean Fever (FMF)

Evidence for the use of this medicine in Familial Mediterranean Fever (FMF) is derived from long-term observational studies and controlled trials. This research examined patients diagnosed with FMF, including both adults and children aged 4 and older. The core focus of this research was to track outcomes related to the frequency and intensity of recurring inflammatory attacks and the length of time patients experienced periods of symptom stability. Studies monitored patient responses over defined time intervals, sometimes spanning several years, reporting how symptoms evolved in the observed populations. Research describes patterns related to the occurrence rate of acute, episodic manifestations of the condition. What remains uncertain is the limited information available regarding certain patient sub-groups, meaning that subgroup findings are uncertain for the general FMF population.

Key Studies & References

1. Colchicine: MedlinePlus Drug Information (Gout and Familial Mediterranean Fever)
2. COlchicine for Recurrent Pericarditis (CORP) Trial - American College of Cardiology

Common questions about Colchicine Stada (FAQ)

Q: Is Colchicine Stada a painkiller?

According to official regulatory documents, Colchicine is specifically classified as an anti-gout agent that works by modulating the body’s inflammatory processes. It is generally not classified as an analgesic medication (painkiller) and is not intended to be used for the treatment of pain from causes other than its approved indications.

Q: How quickly does Colchicine Stada start to work?

The medicine's official product information indicates that the active ingredient, colchicine, reaches its maximum concentration in the blood fairly quickly after being taken orally. This peak concentration, known as C max, is observed in healthy adults approximately 1.3 hours after taking the tablet, with a typical range of 0.7 to 2.5 hours.

Q: Can Colchicine Stada make you tired or dizzy?

While the most frequently reported side effects are related to the gastrointestinal system, postmarketing reports in official documents mention effects on the nervous system. These reports have included symptoms such as fatigue (tiredness) and sometimes dizziness or lightheadedness.

Q: If I have a lactose intolerance, can I still take Colchicine Stada?

Some formulations of Colchicine Stada contain lactose as an inactive ingredient (excipient). Official documentation states that this medicine is not recommended for use in patients with rare, hereditary problems such as galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.

Q: Does Colchicine Stada interact with antibiotics?

Colchicine interacts with other medicines that block its clearance pathways in the body, specifically strong CYP3A4 enzyme inhibitors. This group includes certain antibiotics (such as Clarithromycin). Co-administration with these types of medicines is considered a contraindication in patients who also have existing kidney or liver impairment, as it significantly raises the risk of serious side effects.

Q: Can Colchicine Stada be taken with other medicines that cause tiredness?

Official safety information indicates that Colchicine Stada can potentially cause effects on the nervous system and muscle tissue. Due to this, there may be a potential for additive effects when taken concurrently with other medicines that also cause tiredness or affect the central nervous system.

Q: What happens if Colchicine Stada is taken by accident?

Official regulatory documents contain serious safety warnings regarding the inherent toxicity of this medicine. There have been reports of fatal overdoses in both adults and children, underscoring the high toxicity potential of the medicine. Official guidance emphasizes the importance of secure storage and keeping the medicine out of the reach of children.

Q: How long does Colchicine stay in your system?

The elimination of the medicine from the body is relatively slow. Official pharmacokinetic data indicates that the active substance, colchicine, has a mean elimination half-life of approximately 26.6 to 31.2 hours in young, healthy adults. The half-life describes the time it takes for half of the drug to be eliminated from the body.

Q: Is it possible to be allergic to Colchicine Stada?

Yes. Official labeling states that the medicine is contraindicated (not recommended for use) in patients who have a known hypersensitivity or allergy to the active substance or to any of the inactive ingredients (excipients) used in the tablet formulation.

Q: Is it safe to drive after taking Colchicine Stada?

Regulatory documentation advises that due to possible side effects like dizziness and other reported effects on the nervous system, the medicine may have an influence on a person's ability to drive vehicles or operate machinery.

How to Store and Dispose of Colchicine Stada?

Colchicine tablets must be stored and handled according to regulatory requirements to ensure stability and safety.

Storage Conditions

Requirement	Official Labeled Condition
Temperature	Store at Controlled Room Temperature (20^circ to 25 C / 68^circ to 77 F). Do not store above 25 C.
Protection	Protect from light and moisture.
Container	Keep in the original, tightly closed, light-resistant container with a child-resistant closure.
Child Safety	Keep out of the sight and reach of children due to high toxicity.

---

Disposal Instructions

Unused or expired medicinal product must be disposed of in accordance with local requirements. The medicine must not be disposed of via wastewater or household waste; consult a pharmacist for proper disposal methods.